NEW DELHI — In a major move to accelerate its market consolidation and regional footprint, leading omnichannel diagnostics service provider Redcliffe Labs has announced the appointment of Kshitiz Singh as its new Chief Business Officer (CBO) – Inorganic Growth.
The high-profile executive onboarding positions the healthcare unicorn to aggressively pursue strategic acquisitions, healthcare partnerships, and platform integrations across India’s rapidly evolving diagnostic landscape.
Executive Profile and Industry Pedigree
Singh joins Redcliffe Labs with an extensive 26-year track record of leadership spanning the diagnostics, healthcare, pharmaceutical, and fast-moving consumer goods (FMCG) sectors.
Before stepping into his new role at Redcliffe Labs, Singh served as the General Manager and Business Head at Agilus Diagnostics (formerly SRL Diagnostics). His deep commercial strategy and sales leadership experience also includes high-level tenures at marquee global and domestic enterprises:
-
Diagnostics & Healthcare: Agilus Diagnostics
-
Pharmaceuticals & Lifesciences: Abbott India, Piramal Enterprises, Sanofi, AstraZeneca, and GlaxoSmithKline (GSK)
-
FMCG: Heinz India
Leadership Matrix and Strategic Vision
The appointment highlights Redcliffe Labs’ strategic pivot toward inorganic expansion, looking to integrate established regional diagnostic assets under its tech-driven ecosystem.
Corporate Command Structure:
-
Appointee: Kshitiz Singh
-
Designated Portfolio: Chief Business Officer (CBO) – Inorganic Growth
-
Enterprise: Redcliffe Labs
-
Core Objective: Identifying M&A opportunities, forging regional clinical partnerships, and expanding the brand’s preventive healthcare network.
“The diagnostics industry is entering a phase where scale, integration, and regional reach will define long-term leadership. Across the country, several strong regional diagnostic businesses have built deep clinical expertise and patient trust. We see a significant opportunity to bring these strengths together through an integrated platform… Kshitiz’s experience across diagnostics and healthcare will help us accelerate this journey.” — Aditya Kandoi, Founder & CEO, Redcliffe Labs
Charting the Next Phase of Healthcare Consolidation
Singh’s mandate comes at a vital turning point for India’s tier-2 and tier-3 healthcare markets. As standalone and regional labs face rising technological demands, Redcliffe Labs aims to act as a consolidating force.
In his role as CBO of Inorganic Growth, Singh will spearhead the identification of high-potential regional players, lead cross-border corporate alliances, and integrate local clinical expertise with Redcliffe’s highly automated centralized lab infrastructure, bringing high-quality, tech-enabled preventive diagnostics to a wider pan-India demographic.
